Servizo
Oncoloxía radioterápica
Publicacións (11) Publicacións nas que participase algún/ha investigador/a
2022
-
Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort
Advances in Radiation Oncology, Vol. 7, Núm. 3
-
Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466
-
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864
-
Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer
Radiotherapy and Oncology, Vol. 176, pp. 138-148
-
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity
International Journal of Radiation Oncology Biology Physics, Vol. 114, Núm. 3, pp. 494-501
-
One-year mortality after ICU admission due to COVID-19 infection
Intensive Care Medicine
-
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
Lung Cancer, Vol. 166, pp. 228-241
-
Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy
Reports of Practical Oncology and Radiotherapy, Vol. 27, Núm. 3, pp. 428-439
-
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients
Radiotherapy and Oncology, Vol. 176, pp. 127-137
-
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
eBioMedicine, Vol. 84
-
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Radiotherapy and Oncology, Vol. 168, pp. 75-82